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ABSTRACT 
Long non-coding RNAs (lncRNAs) have been found to show important regulatory roles in various human cancers. 
Lnc-RNA PANDAR is a novel identified lncRNA that was previously reported to show abnormal expression 
pattern in various cancers. However, little is known of its expression and biological function in thyroid cancer. 
Here, we used the quantitative real-time PCR (qRT-PCR) to determine the expression of PANDAR in 64 thyroid 
cancer tissues. We found that expression of PANDAR was up-regulated in thyroid cancer tissues compared with 
adjacent non-tumor tissues. Functional assays in vitro demonstrated that knockdown of PANDAR could inhibit 
proliferation, cell cycle progression, induces the apoptosis, inhibit invasion of thyroid cancer cells. Thus, our study 
provides evidence that PANDAR may function as a potential target for treatment for patients with thyroid cancer. 
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INTRODUCTION 
Thyroid cancer (TC) is originated from 
follicular or parafollicular thyroid cells which 
is one of the most common malignant tumors 
of endocrine organs and has been steadily in-
creasing in morbidity and mortality over the 
years (Vuong et al., 2017). The incidence of 
TC has been increased by an average of 4.5 % 
per year from 2007 to 2011 in United States, 
and has ranked the eighth most frequent can-
cer in China. Thus the rapid increase in TC 
incidence poses a substantial burden (Chen et 
al., 2016; Siegel et al., 2016; Wang and 
Wang, 2012). Previous studies refer that radi-
ation, chemotherapy, and surgery are the 
common treatment methods for thyroid can-
cer, but they all produce poor satisfaction 
(Hay et al., 2013; Nagaiah et al., 2011). In ad-
dition to environmental and genetic predis-
posing factors, increasing studies have shown 
that epigenetic alteration may play pivotal 
roles in the development and progression of 
various kinds of tumors including thyroid 
cancer (Feinberg et al., 2006; Zhang et al., 
2008).  
LncRNAs, which act as an important 
component of tumor biology, are involved in 
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a number of regulatory functions including 
modulation of apoptosis and invasion, repro-
gramming of induced pluripotent stem cells, 
marker of cell fate and parental imprinting 
(Halley et al., 2014; Li and Wang, 2012). And 
it is well recognized that some altered expres-
sion of lncRNAs has been frequently linked 
with cancer pathogenesis (Hu et al., 2016; Li 
et al., 2014; Prensner et al., 2011; Wang et al., 
2015a, b), providing new insight into the ge-
netic and molecular mechanisms of cancer. 
PANDAR, promoter of CDKN 1A antisense 
DNA damage activated RNA, is a novel non-
coding RNA mapping to 6p21.2, which un-
derlies metastatic progression and chromoso-
mal instability in multiple cancer. Recently, 
Han et al. (2015) reported that lncRNA PAN-
DAR was induced in a p53-dependent manner 
and interacts with the transcription factor NF-
YA to limit the expression of pro-apoptotic 
genes. Moreover, lncRNA PANDAR regu-
lates the G1/S transition of breast cancer cells 
by suppressing p16 (INK4A) expression 
(Sang et al., 2016). And PANDAR functions 
as an oncogene in bladder cancer, promoting 
cellular proliferation, migration and apoptosis 
(Zhan et al., 2016). Furthermore, Han et al. 
demonstrated that low expression of long 
non-coding RNA PANDAR predicts a poor 
prognosis of non-small cell lung cancer and 
affects cell apoptosis by regulating Bcl-2(Han 
et al., 2015). However, the expression and de-
tailed function of PANDAR in thyroid cancer 
remains largely unknown and needs to be in-
vestigated. 
In this study, we explored the expression 
pattern of PANDAR in thyroid cancer tissues 
and thyroid cancer cell lines. Furthermore, the 
biological function of lncRNA-PANDAR in 
thyroid cancer cell, proliferation, cell cycle 
and apoptosis was examined in vitro.  
 
MATERIALS AND METHODS 
Patients and tissue samples of TC 
Sixty-four paired samples of TC and adja-
cent non-tumor tissues (more than 2 cm away 
from the tumor) were obtained from patients 
who received surgery in Daping Hospital, 
Third Military Medical University. Tissue 
samples were collected, immediately snap 
frozen in liquid nitrogen and stored at −80 °C 
until further analysis. Before the use of these 
clinical materials for research purposes, in-
formed consents were provided by all patients 
and approval of the Ethics Committee of Dap-
ing Hospital, Third Military Medical Univer-
sity was obtained. The experiment protocol 
was approved by the Ethics Committee of 
clinical laboratory. 
 
Cell culture and siRNA transfection 
Normal human thyroid follicular epithe-
lial cell Nthy-ori3-1 cell and human thyroid 
cancer K-1, TPC-1, SW579, FTC133 and 
XTC-1 purchased from American Type Cul-
ture Collection (ATCC) were cultured in 
RPMI-1640 medium with 10 % fetal bovine 
serum (FBS), 0.1 mM non-essential amino ac-
ids, 1 mM sodium pyruvate, and 1 % penicil-
lin–streptomycin (Sigma, USA) in the humid-
ified incubator with 5 % CO2 at 37 °C. Cells 
were grown in monolayer and conventionally 
passaged when cell attachment rate reached 
90 %. 
The PANDAR-siRNA expression vector 
was constructed based on the full length of 
wild-type lncRNA-PANDAR coding se-
quence by Genechem Biotech (Shanghai, 
China). The target sequence for siRNA- 
PANDAR vector construction was antisense: 
PANDAR-1: 5’-GCAATCTACAACCTGTC 
TT3’, PANDAR-1:5’TTTCGAACGGAAC 
AGAGACUUAUACAGATT-3’. SiRNA 
vector with no silenced PANDAR sequence 
(si-NC) was transfected into thyroid cancer 
cells as the controls. Cells were plated and 
cultured in growth media until cell density 
reached 70 % prior to siRNA transfection and 
cell transfections were conducted with 
Lipofectamine 2000 reagent based on the 
manufacturer’s protocol (Invitrogen, USA). 
Cells were harvested after 48 h for qRT-PCR 
and Western blot analyses. 
 
Cell viability assay 
Cell viability was detected using 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazo-
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lium bromide (MTT) assay as previously de-
scribed (Cohen et al., 2002). Briefly, after be-
ing transfected with siRNA-PANDAR or 
control siRNA vector for 24 h, thyroid cancer 
cells were trypsinized and plated in 96-well 
plates at a density of 5×103 cells/well. After 
24 h of cultivation, supernatant was aban-
doned, and 20 μL of MTT was allowed to be 
added in for another 4-h incubation in RPMI-
1640 supplemented with 10 % FBS. Conse-
quently, 150 μL of dimethylsulfoxide 
(DMSO) was mixed with the cells for 10 min. 
Absorbance of cells in each well was ob-
served at 570 nm under an absorption spectro-
photometer (Olympus, Japan) for the cell 
number calculation. 
 
Clonogenic assay 
Clonogenic assay was performed with a 
modification of previously published method 
(Franken et al., 2006). In brief, after comple-
tion of siRNA transfection, cells were plated 
into the 6 wells plate in triplicate and at a cell 
density of 100 cells/well. Then, the cells were 
grown in RPMI-1640 containing 10 % FBS 
for 14 days. After that, the cells were fixed 
and stained with Crystal violet, followed with 
air-dry. Finally, colonies were counted under 
microscope (IX83, Olympus), and cell num-
ber each colony was at least 30 cells. 
 
Cell apoptosis and cell cycle assay 
After transfection with siRNA, cells were 
cultured in RPMI-1640 containing 10 % FBS 
for another 48 h, and then, the cells were tryp-
sinized and apoptosis was detected using the 
Annexin V-FITC Apoptosis Detection Kit 
(BD, USA). Consequently, cells were pelleted 
and washed with cold PBS suspended with 
cold PBS. The TPC and SW579 cells were 
then treated with Annexin V-propidium io-
dide (PI) in the dark at room temperature ac-
cording to the manufacturer’s instructions. 
The cells were kept on ice in the dark and im-
mediately analyzed by flow cytometry 
(FACSCalibur, BD Biosciences) and the data 
were analyzed using the Cell Quest software. 
For cell cycle analysis, TPC and SW579 cells 
transfected with Si-NC or Si-PANDAR were 
harvested for 48 h. Then cells were fixed with 
70 % ethanol at −20 °C for 12 h and stained 
with propidium iodide (PI) (Sigma) in the 
presence of Ribonuclease A (Takara Biotech-
nology, Dalian, China) for 30 min at room 
temperature. The cell cycle distribution was 
analyzed by flow cytometry (FACSCalibur, 
BD Biosciences). All the experiments were 
repeated three times. 
 
Quantitative Real-time PCR 
Total RNA was isolated from thyroid can-
cer tissues and thyroid cancer cell lines using 
TRIzol Reagent (Invitrogen). RNA was re-
verse transcribed using SuperScript First 
Strand cDNA System (Invitrogen) according 
to the manufacturer’s instructions. Quantita-
tive PCR was conducted using SYBR Green 
Taq Mix (Takara) on a Bio-Rad Real-Time 
PCR System, and GAPDH was used as inter-
nal control for normalization. The primers 
were synthesized by Invitrogen (Shanghai, 
China). Their sequences were as follows: 
PANDAR primers, forward: 5′-
CTGTTAAGGTGGTGGCATTG-3′, re-
verse: 5′-GGAGGCTCATACTGGCTGAT-
3′; GAPDH primers, forward: 5′- CGCTCT 
CTGCTCCTCCTGTTC-3′, reverse: 5′-
ATCCGTTGACTCCG ACCTTCAC-3′. Ex-
periments were repeated at least three times. 
 
Western blotting  
Protein homogenates were prepared from 
thyroid cancer cell lines. Equal amounts of 
protein (50 μg) were separated by SDS/PAGE 
(10 % gel), transferred on to nitrocellulose 
membranes and blocked by 5 % non-fat milk. 
The membranes were incubated with primary 
antibodies at 4 °C for 12 h, and then were in-
cubated with horse radish peroxidase (HRP)-
conjugated secondary antibodies at room tem-
perature for 1 hour. The antibody-antigen re-
actions were visualized by using the ECL Plus 
Western Blotting Detection System (GE 
Healthcare, Piscataway, NJ). The density of 
blots was analyzed by ImageJ software (Na-
tional Institutes of Health, Bethesda, MD). 
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The antibodies were purchased from Cell Sig-
naling Technology and were used at manufac-
turer-recommended dilutions.  
 
Statistical analysis 
All data in this study are expressed as 
mean ± SD, and differences between groups 
were determined using analysis of variance 
(ANOVA) with SPSS version 18.0. P < 0.05 
was considered statistically significant.  
 
RESULTS 
LncRNA-PANDAR expression was upregu-
lated in thyroid tissues and cell lines 
To investigate the roles of PANDAR in 
thyroid pathogenesis, expressions of PAN-
DAR in thyroid cancer tissue (a total of 64 pa-
tients) and in five kinds of cell lines were de-
tected using qRT-PCR (Figure 1). Results 
showed that the relative PANDAR mRNA ex-
pression in thyroid cancer tissues was signifi-
cantly high compared to that in adjacent nor-
mal tissues (Figure 1A, P < 0.001). Interest-
ingly, relative PANDAR expression in five 
kinds of cell lines (K1, TPC-1, SW579, 
FTC133, XTC-1) were all significantly higher 
than that in normal cell line Nthy-ori 3-1 (Fig-
ure 1B, P < 0.01). 
Knockdown of PANDAR impairs  
proliferation and invasion of TPC-1 and 
SW579 cells in vitro 
As shown in Figure 1B, PANDAR ex-
pression in TPC-1 and SW579 was compara-
tively higher than that of the other three kinds 
of cell lines. Therefore, we selected TPC-1 
and SW579 cell lines as a model to investigate 
the effect of PANDAR on cell proliferation 
and apoptosis.  
We knocked down PANDAR expression 
in TPC-1 and SW579 cancer cells by transfec-
tion with NC-siRNAs, si-PANDAR. As 
shown in Figure 2A, cells transfected with si-
PANDAR presented a significantly decreased 
mRNA expression level of PANDAR com-
pared with the Si-NC group in both cells by 
qRT-PCR (P < 0.05; Figure 2A). To deter-
mine the effect of PANDAR on the viability 
and proliferation of thyroid cancer cell in 
vitro, MTT assays showed that knockdown of 
PANDAR obviously suppressed the viability 
of TPC-1 and SW579 in a time dependent 
manner (P < 0.05; Figure 2B-D). The ability 
to form colonies by TPC-1 and  SW579 cells 
was also suppressed significantly after knock-
down of PANDAR when compared with that 
 
 
Figure 1: LncRNA PANDAR expression is increased in thyroid cancer tissues and cell lines. A. Relative 
expression of PANDAR in 64 pairs of thyroid cancer tissues and adjacent non-tumor tissues by qRT-
PCR analysis. ***P<0.001 compared with non-tumor control. B. The expression levels of PANDAR in a 
panel of thyroid cancer cell lines were determined by qRT-PCR and compared with that in human normal 
thyroid cells (Nthy-ori 3–1). **P < 0.01 compared with the Nthy-ori 3-1 cell. Data represent the mean ± 
SD from three independent experiments. *P < 0.05; **P < 0.01. 
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Figure 2: The effect of PANDAR expression on cell viability and proliferation of thyroid cancer cells. A. 
qPCR analysis of PANDAR expression levels following the treatment of TPC-1 and SW579 cells with 
siRNAs against PANDAR. B and C. MTT assay showed knockdown of PANDAR inhibited two types of 
thyroid cancer cells’ viability. D. Soft-agar assay measuring colony formation of PANDAR knockdown 
cells. E. Cell invasion of the two types of thyroid cancer cells measured with transwell assay (scale bar: 
100 μm). F. Cell count of the invaded cells (per view) based on the transwell invasion assay. Colony 
number was normalized to that obtained with cells transfected with Si-NC, which was set to 100%. 
Silencing of PANDAR significantly decreased the colony-forming ability. Each assay was performed in 
triplicate. Data are mean ± SD. * P < 0.05, **P < 0.01. 
 
 
 
by the negative controls (P < 0.01; Figure 
2D). These results showed that PANDAR de-
pletion had an obvious inhibitory effect on the 
growth of thyroid cancer cells. Furthermore, 
knockdown of PANDAR resulted in attenu-
ated invasion of TC cells measured by 
transwell invasion assay (Figure 2E, F). 
 
Knockdown of PANDAR suppressed cell 
cycle progression of thyroid cancer cells 
Having found the effect of PANDAR 
downregulation on the proliferation of thyroid 
cancer cell lines, we then examined the im-
pact of decreased expression of PANDAR on 
cell cycle in thyroid cancer cells. Flow cy-
tometric analysis showed a decrease in  the 
percentage of cells in the S phase and a 
marked accumulation in the percentage of 
cells in the G0/G1 phase in the Si-PANDAR 
groups in TPC-1 and SW579 cells (Figure 3A 
and B), compared with the Si-NC groups. Ac-
cordingly, to verify whether PANDAR could 
indeed arrest the cell cycle in G0/G1 stage or 
not, cell cycle-related protein expression in-
cluding cyclin D1, Chk1, and Cdc25A were 
analyzed. These cell cycle regulatory proteins 
were significantly decreased when cells were 
transfected with Si-PANDAR compared to 
that in controls (Figure 3C). Taken together, 
these results illuminated that PANDAR may 
function as an oncogene involved in the stim-
ulation of thyroid cancer cell proliferation. 
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Figure 3: Effect of PANDAR knockdown on cell cycle. A. Cell cycle distribution was measured by pro-
pidium iodide staining followed by flow cytometry. B. The two cells had cell-cycle arrest at the G0-G1 
phase compared with cells transfected with Si-NC. C. Western blotting was used to detect the protein 
expression of Chk1, Cdc25A and CyclinD1; β-actin was used as control. Each assay was performed in 
triplicate. Data are mean ± SD. *P < 0.05, **P < 0.01.  
 
 
 
Knockdown of PANDAR increased the 
apoptosis of thyroid cancer cells 
As shown by flow cytometry analysis in 
Figure 4A and B, compared with the cells 
transfected with si-NC, si-PANDAR treat-
ment caused increased apoptosis in TPC-1 
and SW579 cells significantly (P < 0.01, 
TPC-1 and P < 0.05, SW579). Moreover, we 
examined Bcl-2 and Bax expression in thy-
roid cancer cells in response to PANDAR 
knockdown. As is well known, Bcl-2 is rec-
ognized to inhibit apoptosis and facilitate re-
sistance to multifarious apoptosis-inducing 
factors. While, Bax could inhibit the anti-
apoptotic effect of Bcl-2 by forming a hetero-
dimer with Bcl-2. Western blotting analysis 
indicated that PANDAR knockdown sup-
pressed the protein expression of Bcl-2 and in 
contrast enhanced the protein expression of 
Bax in TPC-1 and SW579 cells (Figure 4C). 
 
DISCUSSION 
Recently, increasing evidence has sug-
gested that lncRNAs may play vital regula-
tory roles in the development of various types 
of cancers (Cheetham et al., 2013; Shore et 
al., 2012). A number of papers have shown 
that PANDAR show abnormal expression 
pattern in various cancers (Lu et al., 2017; 
Peng and Fan, 2015; Zhan et al., 2016), how-
ever, few have reported the potential roles of 
lncRNA PANDAR in thyroid cancer. In the 
present  study, we  found  that PANDAR was 
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Figure 4: Downregulated lncRNA PANDAR increased the apoptosis of thyroid cancer cells. A. Apopto-
sis of TPC-1 and SW579 cell lines was determined by flow cytometry. B. Histogram of percentage of 
apoptotic cells, according to (A). C. Western blotting was used to detect the protein expression of Bcl-2 
and Bax; β-actin was used as control. Each assay was performed in triplicate. Data are mean ± SD. *P 
< 0.05, **P < 0.01 
 
 
 
highly expressed in thyroid cancer tissues and 
cell lines. In addition, loss of function assay 
revealed that knockdown of PANDAR signif-
icantly impaired the proliferation and inva-
sion, and also arrested the cell cycle at G0/G1 
stage and significantly decreased cyclin D1 
expression in thyroid cells. Moreover, 
lncRNA PANCAR could induce cell apopto-
sis of thyroid cells. 
PANDAR has been implicated in the de-
velopment of various cancers, including colo-
rectal cancer, where the high expression of 
PANDAR indicates a poor prognosis and pro-
motes metastasis by EMT pathway (Lu et al., 
2017), and increased expression of PANDAR 
predicts a poor prognosis in gastric cancer 
(Ma et al., 2016). Moreover, low expression 
of long noncoding RNA PANDAR predicts a 
poor prognosis of non-small cell lung cancer 
and affects cell apoptosis by regulating Bcl-2 
(Han et al., 2015). In this study, the data 
showed that PANDAR was significantly up-
regulated in thyroid cancer tissues compared 
to its adjacent normal tissues, as well as in the 
five kinds of tumor cell lines (Figure 1). 
Therefore, we speculated that PANDAR 
overexpression may be correlated with thy-
roid cancer pathogenesis. 
Accordingly, the effects of PANDAR ex-
pression on thyroid cancer cell proliferation 
were further analyzed using siRNA-mediated 
gene silencing. Our results showed that thy-
roid cancer cell proliferation and colony for-
mation were significantly suppressed by 
siRNA-PANDAR transfection (Figure 2), in-
dicating that PANDAR could promote thy-
roid cancer cell proliferation. Consequently, 
we further analyzed the effects of PANDAR 
expression on thyroid cell cycle and cell cy-
cle-associated protein expression. Our data 
showed that thyroid cell cycle was arrested at 
G0/G1 stage by silencing PANDAR, and cell 
cycle-associated protein Chk1, Cdc25A and 
cyclin D1 expression was significantly de-
creased (Figure 3).  
Defective apoptosis is one of the hall-
marks of cancer cells and increasing cell 
apoptosis could prevent cancer progression. 
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Knockdown of PANDAR by siRNA induced 
apoptosis of thyroid cells by decreasing Bcl-2 
expression and activating Bax (Figure 4), in-
dicating that PANDAR inhibition could in-
duce thyroid cancer cell apoptosis. 
In summary, the findings from our study 
demonstrated that the downregulation of the 
PANDAR expression inhibits cell prolifera-
tion, arrests cell cycle and facilitates apopto-
sis. Thus, PANDAR could be a promising 
therapeutic target and novel molecular bi-
omarker for TC. 
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